New Preservative-Free eye drops take on glaucoma in Head-to-Head trial

NCT ID NCT06394973

Completed Disease control Sponsor: Laboratoires Thea Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested two strengths of a new eye drop called T4090 against the existing drug Rhopressa in 161 adults with open-angle glaucoma or ocular hypertension. The goal was to see which better lowers eye pressure over 7 weeks. Participants used one drop daily in each eye. The study aims to find a safe and effective alternative for managing these chronic eye conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T4090 (kinezodianone hydrochloride) eye drops
What this could lead to: If successful, T4090 could offer a new preservative-free option to lower eye pressure in glaucoma patients.
What could go wrong: This is a small Phase 2 trial, so results may not confirm effectiveness or safety. It only compares to one existing drug and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA OCULAR HYPERTENSION

Contacts and locations

Locations

Alterman, Modi and Wolter Ophthalmic Surgeons

Poughkeepsie, New York, 12603, United States
Arizona Advanced Eye Research Institute

Glendale, Arizona, 85306, United States
Coastal Research Associates, LLC

Roswell, Georgia, 30076, United States
DCT-Shah Research, LLC sba Discovery Clinical Trials

Mission, Texas, 78572, United States
East Coast Institute for Research, LLC

Jacksonville, Florida, 32256, United States
Emerson Clinical Research Institute

Falls Church, Virginia, 22046, United States
Eye Research Foundation

Newport Beach, California, 92663, United States
Glaucoma Associates of Texas

Dallas, Texas, 75231, United States
Global Research Management, Inc.

Glendale, California, 91204, United States
Houston Eye Associates

Houston, Texas, 53719, United States
Houston Eye Associates

Houston, Texas, 77008, United States
James D. Branch, MD

Winston-Salem, North Carolina, 27101, United States
Keystone Research

Austin, Texas, 78731, United States
Mild Florida Eye Center

Mt. Dora, Florida, 32757, United States
North Bay Eye Associates

Petaluma, California, 94954, United States
Piedmont Eye Center

Lynchburg, Virginia, 24502, United States
Sacramento Eye Consultants, A Medical Corporation

Sacramento, California, 95815, United States
Segal Drug Trials, Inc

Delray Beach, Florida, 33484, United States
Seidenberg Protzko Eye Associates

Havre de Grace, Maryland, 21078, United States
Shettle Eye Research, Inc.

Largo, Florida, 33773, United States
Total Eye Care, PA

Memphis, Tennessee, 38119, United States
United Medical Research Institute

Inglewood, California, 90301, United States
Visionary Research Institute

Newport Beach, California, 92663, United States
Wolstan and Goldberg Eye Associates

Torrance, California, 90505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.